Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemic episodes. Debilitated or malnourished patients and those with adrenal, pituitary
, renal, or hepatic insufficiency are particularly susceptible to the hypoglycemic action of glucose lowering drugs.
Loss of Control of Blood Glucose:
When a patient stabilized on any antidiabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a temporary loss of glycemic control may occur.
Combination of Glimepiride and Rosiglitazone should be used with caution in patients with edema.
Since thiazolidinediones, including Rosiglitazone can cause fluid retention, which can exacerbate or lead to congestive heart failure, Combination of Glimepiride and Rosiglitazone should be used with caution in patients at risk for heart failure.
Dose-related weight gain was seen with Rosiglitazone alone and in combination with other hypoglycemic agents.
Liver enzymes should be checked prior to the initiation of therapy with combination of Glimepiride and R
The usual starting dose of 1mg/4 mg or 2 mg/4 mg once daily.
The maximum recommended daily dose of is 4 mg of Glimepiride and 8 mg of Rosiglitazone.
The dosage of anti-diabetic therapy should be individualized on the basis of effectiveness and tolerability.